By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Signal Genetics today said that it will use its MyPRS genomic testing platform in a multiple myeloma research program being conducted by Array BioPharma.

According to the New York-based firm, it will provide Array BioPharma with genetic information from patient samples in two upcoming clinical studies on an Array drug candidate. It said that the collaboration may lead to the development of "superior and personalized treatment options for myeloma patients."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.